Vyvanse 50 mg is the appropriate equivalent dose for Adderall XR 20 mg
When converting from Adderall XR 20 mg to Vyvanse (lisdexamfetamine), start with Vyvanse 50 mg once daily. This conversion is based on the pharmacological relationship between these medications and FDA-approved dosing guidelines.
Pharmacological Basis for Conversion
Lisdexamfetamine is a prodrug that is enzymatically converted to dextroamphetamine (d-amphetamine) in the blood 1. Adderall XR contains mixed amphetamine salts in a 3:1 ratio of d-amphetamine to l-amphetamine, with 20 mg Adderall XR providing approximately 12.5 mg of total amphetamine base equivalence 2.
The conversion ratio is approximately 2.5:1 (Vyvanse to Adderall XR). This means:
- Adderall XR 20 mg ≈ Vyvanse 50 mg
- Adderall XR 10 mg ≈ Vyvanse 30 mg
Dosing Algorithm
Starting dose: Begin with Vyvanse 50 mg once daily in the morning 3.
Titration if needed:
- If inadequate response after 1 week, increase by 10 mg weekly increments 3
- Maximum dose: 70 mg daily 3
- If 50 mg produces excessive side effects, reduce to 40 mg
Key Clinical Considerations
Duration of action: Vyvanse provides longer symptom coverage than Adderall XR. Vyvanse demonstrates efficacy up to 14 hours post-dose 4, while Adderall XR has a Tmax of approximately 7 hours 2. This extended duration may benefit patients needing late-day symptom control.
Monitoring requirements:
- Blood pressure and heart rate at baseline and follow-up (amphetamines increase SBP by 1.93 mmHg and DBP by 1.84 mmHg) 5
- Weight monitoring (appetite suppression is common) 6
- Assessment of ADHD symptoms using standardized rating scales 6
Common pitfalls to avoid:
- Do not use a 1:1 conversion ratio—this will result in underdosing
- Do not split the Vyvanse dose; it is designed for once-daily administration 1
- Recognize that Vyvanse requires enzymatic conversion and cannot be crushed or insufflated for abuse, making it preferable in patients at risk for diversion 7
Side Effect Profile
Expect similar side effects to Adderall XR, including decreased appetite, insomnia, dry mouth, and increased heart rate 1, 8. The withdrawal rate due to adverse effects is approximately 2.69 times higher than placebo 9. Most adverse events are mild and do not increase with long-term use 8.
Special Populations
Substance abuse concerns: Vyvanse has lower abuse liability than immediate-release amphetamines because it requires enzymatic conversion to become active 7, 8. This makes it a reasonable choice when diversion is a concern.
Pregnancy: Limited data exist for lisdexamfetamine specifically, but it is converted to dextroamphetamine, which does not appear associated with major congenital malformations 3.